GENB · Generate Biomedicines, Inc. · Webcasts, Transcripts & Audio
$13.06
+0.49 (+3.90%)
At close · Nov 6
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of December 31, 2025, the Company had concluded that there was substantial doubt about its ability to continue as a going concern. Upon closing of the IPO and receipt of the associated cash proceeds, the Company has alleviated the substantial doubt that previously existed, and based on the Company’s current capital resources, which consists of its cash, cash equivalents and marketable securities on hand at June 30, 2026, it expects to have sufficient cash to fund our current operating plan into the first half of 2028.”View the 10-Q filed Aug 6, 2026
Market Cap
$1.68B
Shares
128.35M
Volume · Nov 6
632.2K
Avg daily vol (3M)
1.2M
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Generate Biomedicines, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Generate Biomedicines, Inc. (GENB), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-09-16
Generate Biomedicines, Inc. (GENB) September 16, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-09-15
Generate Biomedicines, Inc. (GENB) Q2 2026 Earnings Call
Revenue
$6.31M
▼ 37.7% YoY Diluted EPS
$-0.52
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Generate Biomedicines, Inc. (GENB) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-08
Generate Biomedicines, Inc. (GENB) June 8, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-07
Generate Biomedicines, Inc. (GENB) Q1 2026 Earnings Call
Revenue
$7.22M
▼ 18.1% YoY Diluted EPS
$-1.07
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Showing 1–5 of 5 webcasts
Key facts
CIK
2100782
CUSIP
370920100
13F (30d)
35 filings
35 filers
Visit website
Investor relations